Table 4. Risk of venous thromboembolism for patients receiving ESAs compared with patients not receiving ESAs: results from five meta-analysesa.
| Meta-analysis | Number of trials | Number of patients | Statistic for VTE risk | 95% Confidence interval |
|---|---|---|---|---|
| Present meta-analysis | 44 | 13 196 | 1.48 OR | 1.28–1.72 |
| Bohlius et al, 2006 | 35 | 6769 | 1.67 RR | 1.35–2.06 |
| Seidenfeld et al, 2006 | 31 | 6412 | 1.68 RR | 1.36–2.08 |
| Ross et al, 2006 | 6 | 1463 | 1.41 OR | 0.81–2.47 |
| Bennett et al, 2008b | 38 | 8172 | 1.57 RR | 1.31–1.87 |
ESA=erythropoiesis-stimulating agent; OR=odds ratio; RR=relative risk; VTE=venous-thromboembolic event.
a
Results from studies conducted in the chemotherapy, radiotherapy and anaemia of cancer (AoC) settings are included.